The DEA Finally Decides To Reschedule Hydrocodone

Last week the DEA released a final rule on the rescheduling of hydrocodone removing it from the schedule III controlled substances list in favor of a schedule II designation. To be clear, this decision specifically addresses hydrocodone combination products (i.e., hydrocodone-acetaminophen formulations such as Vicodin) as hydrocodone by itself has always been a schedule II […]...Read more

New Additions to Tower Executive Team

In our continued commitment  to build a unique MSP compliance model focused on  identification, intervention and involvement to stage claims prior to MSA and settlement, I am pleased to announce the addition of two key individuals to the Tower MSA Partners executive team. Scott E. Yasko, MBA Scott joined tower in July to serve as EVP, […]...Read more